Efficacy and Safety of the Treatment of Chronic Hepatitis C with Sofosbuvir/Ledipasvir in Children Aged 5 to 10 Years with Comorbidities—A Brief Report
The efficacy and safety of 12 weeks of therapy with sofosbuvir/ledipasvir in three patients aged 5–10 years are presented. All three children suffered from comorbidities, including chronic kidney disease in two. All participants achieved a sustained virologic response 12 weeks after the end of treat...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-08-01
|
| Series: | Infectious Disease Reports |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2036-7449/14/4/61 |
| _version_ | 1797409912083447808 |
|---|---|
| author | Maria Pokorska-Śpiewak Anna Dobrzeniecka Agnieszka Ogrodnik |
| author_facet | Maria Pokorska-Śpiewak Anna Dobrzeniecka Agnieszka Ogrodnik |
| author_sort | Maria Pokorska-Śpiewak |
| collection | DOAJ |
| description | The efficacy and safety of 12 weeks of therapy with sofosbuvir/ledipasvir in three patients aged 5–10 years are presented. All three children suffered from comorbidities, including chronic kidney disease in two. All participants achieved a sustained virologic response 12 weeks after the end of treatment. No adverse effects were reported during or after the treatment, and the compliance was good. Decisions on starting treatment in children below 6 years of age should be made individually, taking compliance into consideration. The adjustment of formulation and dosing of medication during treatment is necessary in young children. Further research with larger groups of patients is needed to confirm our findings. |
| first_indexed | 2024-03-09T04:22:23Z |
| format | Article |
| id | doaj.art-db3db9ca2aa14fbfab7ac633574e2e93 |
| institution | Directory Open Access Journal |
| issn | 2036-7449 |
| language | English |
| last_indexed | 2024-03-09T04:22:23Z |
| publishDate | 2022-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Infectious Disease Reports |
| spelling | doaj.art-db3db9ca2aa14fbfab7ac633574e2e932023-12-03T13:46:09ZengMDPI AGInfectious Disease Reports2036-74492022-08-0114457457810.3390/idr14040061Efficacy and Safety of the Treatment of Chronic Hepatitis C with Sofosbuvir/Ledipasvir in Children Aged 5 to 10 Years with Comorbidities—A Brief ReportMaria Pokorska-Śpiewak0Anna Dobrzeniecka1Agnieszka Ogrodnik2Department of Children’s Infectious Diseases, Medical University of Warsaw, 01-201 Warsaw, PolandRegional Hospital of Infectious Diseases in Warsaw, 01-201 Warsaw, PolandPomeranian Center for Infectious Diseases and Tuberculosis, 80-214 Gdańsk, PolandThe efficacy and safety of 12 weeks of therapy with sofosbuvir/ledipasvir in three patients aged 5–10 years are presented. All three children suffered from comorbidities, including chronic kidney disease in two. All participants achieved a sustained virologic response 12 weeks after the end of treatment. No adverse effects were reported during or after the treatment, and the compliance was good. Decisions on starting treatment in children below 6 years of age should be made individually, taking compliance into consideration. The adjustment of formulation and dosing of medication during treatment is necessary in young children. Further research with larger groups of patients is needed to confirm our findings.https://www.mdpi.com/2036-7449/14/4/61childrenchronic kidney diseasedirect acting antiviralhepatitis C virussofosbuvir/ledipasvir |
| spellingShingle | Maria Pokorska-Śpiewak Anna Dobrzeniecka Agnieszka Ogrodnik Efficacy and Safety of the Treatment of Chronic Hepatitis C with Sofosbuvir/Ledipasvir in Children Aged 5 to 10 Years with Comorbidities—A Brief Report Infectious Disease Reports children chronic kidney disease direct acting antiviral hepatitis C virus sofosbuvir/ledipasvir |
| title | Efficacy and Safety of the Treatment of Chronic Hepatitis C with Sofosbuvir/Ledipasvir in Children Aged 5 to 10 Years with Comorbidities—A Brief Report |
| title_full | Efficacy and Safety of the Treatment of Chronic Hepatitis C with Sofosbuvir/Ledipasvir in Children Aged 5 to 10 Years with Comorbidities—A Brief Report |
| title_fullStr | Efficacy and Safety of the Treatment of Chronic Hepatitis C with Sofosbuvir/Ledipasvir in Children Aged 5 to 10 Years with Comorbidities—A Brief Report |
| title_full_unstemmed | Efficacy and Safety of the Treatment of Chronic Hepatitis C with Sofosbuvir/Ledipasvir in Children Aged 5 to 10 Years with Comorbidities—A Brief Report |
| title_short | Efficacy and Safety of the Treatment of Chronic Hepatitis C with Sofosbuvir/Ledipasvir in Children Aged 5 to 10 Years with Comorbidities—A Brief Report |
| title_sort | efficacy and safety of the treatment of chronic hepatitis c with sofosbuvir ledipasvir in children aged 5 to 10 years with comorbidities a brief report |
| topic | children chronic kidney disease direct acting antiviral hepatitis C virus sofosbuvir/ledipasvir |
| url | https://www.mdpi.com/2036-7449/14/4/61 |
| work_keys_str_mv | AT mariapokorskaspiewak efficacyandsafetyofthetreatmentofchronichepatitiscwithsofosbuvirledipasvirinchildrenaged5to10yearswithcomorbiditiesabriefreport AT annadobrzeniecka efficacyandsafetyofthetreatmentofchronichepatitiscwithsofosbuvirledipasvirinchildrenaged5to10yearswithcomorbiditiesabriefreport AT agnieszkaogrodnik efficacyandsafetyofthetreatmentofchronichepatitiscwithsofosbuvirledipasvirinchildrenaged5to10yearswithcomorbiditiesabriefreport |